Study | Year | Country | Diseases | Case Number | Stage | Sample | Assay | Cut-off value | HR | Follow-up (months) | Type of miR-17 detection |
Chen et al | 2012 | China | HCC | 120 | I-IV | Tissue | qRT-PCR | Median | RR | 46 | miR-17–5 p |
Qun et al | 2013 | China | Lung Cancer | 221 | I-IV | Tissue | qRT-PCR | Median | Given | 50 | miR-17 |
Li et al | 2014 | China | Osteosarcoma | 117 | I-III | Tissue | qRT-PCR | Median | Given | 44 | miR-17 |
Lu et al | 2012 | China | Glioma | 108 | I-IV | Tissue | qRT-PCR | Mean | RR | 60 | miR-17 |
Xi et al | 2015 | China | T-cell lymphoblastic lymphoma | 57 | III, IV | Tissue | qRT-PCR | Median | Given | Up to 13 years | miR-17 |
Yu et al | 2012 | China | Colon Cancer | 48 | I-IV | Tissue | qRT-PCR | Median | Given | 5–66 | miR-17 |
Manuel et al | 2011 | Spain | Gastrointestinal Cancer | 38 | I-IV | Tissue | qRT-PCR | Mean | Given | 38 | miR-17 |
Robaina et al | 2016 | Brazil | Burkitt lymphoma | 41 | I-IV | Tissue | qRT-PCR | Median | Given | 69 | miR-17 |
Xu et al | 2014 | China | Esophageal Squamous Cell Carcinoma | 105 | I-IV | Tissue | qRT-PCR | Mean | Given | 52 | miR-17 |
Jun et al | 2010 | Japan | Pancreatic Cancer | 80 | I-IV | Tissue | qRT-PCR | Median | Given | 60 | miR-17–5 p |
Wang et al | 2011 | China | Gastric Cancer | 65 | I-IV | Serum | qRT-PCR | Median | Given | 36 | miR-17–5 p |
Zheng et al | 2013 | China | HCC | 96 | I-IV | Serum | qRT-PCR | Median | Given | NG | miR-17–5 p |